A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Pasireotide (Primary)
- Indications Acromegaly; Gigantism
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Feb 2017.